Phaseline

Companies › Diakonos Oncology

Diakonos Oncology: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DOC1021
Double-loaded dendritic cell vaccine loaded with tumor lysate and mRNA
–Phase 2Glioblastoma (GBM); Refractory MelanomaMar 2030
Peginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Glioblastoma (GBM)Mar 2030
Autologous DC Therapy
Th-1 dendritic cell immunotherapy
–Phase 1Pancreatic AdenocarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04157127Autologous DC TherapyPhase 1Pancreatic AdenocarcinomaOncologyDec 2026
NCT06805305DOC1021Phase 2Glioblastoma (GBM)OncologyMar 2030
NCT06805305Peginterferon Alfa-2APhase 2Glioblastoma (GBM)OncologyMar 2030
NCT07288112DOC1021Phase 1Refractory MelanomaOncologyJan 2031

Targets

IFNAR1 (1) IFNAR2 (1)

Companies with the same targets

PharmaEssentia BriaCell Therapeutics Brii Biosciences Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical

Companies built like this

Allotera Therapeutics HRYZ Biotech Scancell Guangzhou Virotech Pharmaceutical PharmaEssentia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.